Clinical Trials in Norway / NCT04541056
Active, not recruiting Not applicable

Goal Management Training for Adult Survivors of Childhood Leukemia and Non-Hodgkins Lymphoma With Neurocognitive Sequelae

NCT04541056 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2020-09-04
Last updated
2025-08-19

Condition(s) studied

Childhood Non-Hodgkin LymphomaChildhood Acute Lymphoblastic LeukemiaChildhood Acute Myeloid Leukemia

Investigational drug(s) / intervention(s)

Goal Management Training (GMT)Brain Health Workshop (BHW)

Goal Management Training (GMT): The manual comprises an introduction to GMT for the survivors of ALL, and a detailed session structure incorporating cognitive and behavioral tasks. The GMT program involves teaching the participants about goals, attention slips and how to manage these, how to review and prioritize goals (e.g., Stop, Think, Organize, Plan), and how to keep goals in mind (e.g., using analogies such as the mental blackboard). Each session will follow the same general format; namely, facility-delivered presentations, flipchart discussions, group activities and homework.

Brain Health Workshop (BHW): BHW is a psycho-educative control condition, and is typically part of psycho-educative Acquired Brain Injury (ABI) rehabilitation programs, but adjusted for the ALL group of participants. The psycho-educative control condition BHW will be matched GMT for amount of training and therapist contact. Homework assignment and in-session tasks included readings, brain games, puzzles, and practical exercises such as logging sleep.

Study summary

Survivors of childhood cancer are at risk for developing neurocognitive sequelae. Multiple meta-analyses demonstrate significant deficits in overall intellectual abilities, academic functioning and specific cognitive skills among survivors of childhood cancer treated with intrathecal chemotherapy only and/or cranial irradiation. Preventing neurocognitive deficits is therefore of great importance. Unfortunately, intervention studies for this group of survivors are scarce. The main aim of this randomized controlled trial is to determine the efficacy of Goal Management Training (GMT) as a group-based treatment program for 60 adult survivors of childhood leukemia, and non Hodgkins lymphoma, diagnosed between 1980 and 2017 at an age below 18, with attention and executive function deficits. The participants will be randomized to one treatment group (GMT), and one waitlist condition followed by one active control intervention, the "Brain health workshop" (BHW), which has a psycho-educative approach. The follow-up time from diagnosis will be ≥5 years and the age at survey 18-40 years. The study will expand the knowledge base on treatment factors important in improving cognitive function. Results from this study can be implemented in rehabilitation for the young adult survivors of childhood leukemia, and non Hodgkins lymphoma, which will be of importance for their future educational and work-related functioning.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
The Norwegian Cancer Registry will identify participants based on the following criteria: * Acute Lymphoblastic Leukaemia (ALL), Acute Myelogen Leukemia (AML), non Hodgkins Lymphoma diagnosed between 1980 - 2017 * Age when diagnosed \<18 år (0-17years) * Age at survey 18-40 years * Born between 1980 - 2004 * Minimum five years (≥5) post ALL, AML, NHL diagnosis * ALL, AML, NHL treatment at Oslo University Hospital and St. Olavs Hospital Inclusion Criteria Screening/baseline: * Written informed consent * ≥5 years from diagnosis * Age 18-40 * Without cancer recurrence the last five years * Understand and speak Norwegian Additional inclusion criteria for the intervention: * Experiencing executive dysfunction as determined by a semi-structured interview * Cognitive capacity to engage with the training, and General Ability Index (GAI) Score ≥70 measured by Wechsler Intelligence Scale for Adults (WAIS-IV) Exclusion Criteria: * Cancer recurrence within the last five years * A history of premorbid Central Nervous System (CNS) injury or disease (e.g., Traumatic brain injury with noticeable cognitive changes, loss of consciousness or injury discovered on CT or MR) * Pre-existing attention deficit hyperactivity disorder (ADHD) * Motor or sensory damage impeding study participation * A major psychiatric disease and/or ongoing substance abuse impeding study participation * Present suicidal ideation * Down syndrome

Primary outcome measure(s)

Trial sites (3)

FacilityCityRegionStatus
Oslo University Hospital - Rikshospitalet Oslo Norway
St. Olavs Hospital Trondheim Norway
Department of Psychology, Norwegian University of Science and Technology (NTNU) Trondheim Norway

More Norwegian University of Science and Technology trials in Norway

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04541056 on ClinicalTrials.gov ↗ ← All trials in Norway